No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
4basebio Plc operates as a biotechnology firm dedicated to the creation of advanced therapeutic medicinal products. Its strategy involves utilizing synthetic DNA and non-viral platforms specifically engineered for targeted nucleic acid delivery to cells. The company actively produces and supplies premium synthetic DNA suitable for diverse applications, including research, therapeutic interventions, and pharmacological uses. Moreover, 4basebio develops specialized non-viral vectors, designed to ensure the effective transportation of various therapeutic payloads within patients. This enterprise was established on December 22, 2020, and maintains its principal office in Cambridge, United Kingdom.
www.4basebio.comNo one on the platform currently holds 88Q.DE.
No tracked institution reports a position in 88Q.DE as of their last filing.
No one on the platform has traded 88Q.DE yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 81.6% | 29.7% | ||||
| Profit Margin % | -998.5% | -1342.8% | ||||
| Free Cash Flow Margin % | -898.3% | -1494.2% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $3M | +67.1% | $-1.01 | $-1.03–$-1.00 | — | 1 |
| 2027 | $12M | +328.6% | $-0.61 | $-0.62–$-0.60 | — | 1 |
| 2028 | $25M | +108.3% | $-0.20 | $-0.21–$-0.20 | — | 1 |
| 2029 | $36M | +40.0% | $0.20 | $0.20–$0.21 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 1 of the last 2 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-22 | $-0.68 | $-0.68 | +0.0% |
| 2023-09-21 | $-0.33 | $-0.34 | -3.3% |
| $112M |
| — |
| NP5.DENewron Pharmaceuticals S.p.A. | $11.70 | -2.50% | $243M | — |
| VX1.DEVertex Pharmaceuticals Incorporated | $449.55 | +1.81% | $114.1B | — |
Source: Financial Modeling Prep · peers by sector/industry